文献速递心力衰竭与心肌病心律失常

肥厚型心肌病患者左室射血分数低正常值的预后研究

Prognosis of patients with hypertrophic cardiomyopathy and low-normal left ventricular ejection fraction.
PubMed 文献 · Heart · 2023-04-25

该回顾性研究纳入两家三级医院2008至2019年间1858例肥厚型心肌病患者,按左室射血分数(LVEF)分为保留(≥60%)、低正常(50%-60%)和降低(<50%)三组。中位随访4.09年,低正常LVEF是心衰住院和心血管死亡的独立预测因子,而LVEF降低是SCD/等效事件的独立预测因子并增加传统HCM-SCD风险模型的预测价值。

要点

  • 低正常LVEF(50%-60%)的HCM患者心衰住院和心血管死亡风险显著高于LVEF保留者。
  • LVEF降低(<50%)是SCD/等效事件的独立预测因子,并改善HCM-SCD风险模型的预测能力。
  • LVEF与全因死亡无显著关联。

核心结论

  • 低正常LVEF是HCM患者心衰住院和心血管死亡的独立预测因子。
  • LVEF降低是SCD/等效事件的独立预测因子,并增加HCM-SCD风险模型的预测价值。

研究设计与样本

  • 回顾性研究,纳入两家三级医院2008至2019年间1858例HCM患者。
  • 按LVEF分为保留(≥60%,1399例)、低正常(50%-60%,415例)和降低(<50%,44例)三组。
  • 主要终点为SCD、室速/室颤和适当ICD放电的复合终点;次要终点包括心衰住院、心血管死亡和全因死亡。

主要发现

  • 中位随访4.09年,主要终点发生率为1.9%,心衰住院、心血管死亡和全因死亡发生率分别为3.3%、1.9%和5.3%。
  • LVEF降低是SCD/等效事件的独立预测因子(aHR 5.214,95%CI 1.574-17.274,p=0.007),对HCM风险-SCD模型有增量预测价值(NRI 0.625)。
  • 与LVEF保留者相比,低正常LVEF患者心衰住院风险升高(aHR 2.457,95%CI 1.423-4.241,p=0.001),心血管死亡风险升高(aHR 2.641,95%CI 1.314-5.309,p=0.006)。
  • 与LVEF保留者相比,LVEF降低患者心衰住院风险升高(aHR 7.937,95%CI 3.315-19.002,p<0.001),心血管死亡风险升高(aHR 5.405,95%CI 1.530-19.092,p=0.009)。
  • LVEF与全因死亡无显著关联。

临床怎么用

  • 对HCM患者应关注LVEF低正常值(50%-60%),其心衰住院和心血管死亡风险已升高。
  • LVEF降低(<50%)可用于SCD风险分层,考虑纳入传统HCM-SCD风险模型以改善预测。

局限性

  • 回顾性研究设计。
  • LVEF降低组样本量较小(44例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether low-normal left ventricular ejection fraction (LVEF) is associated with adverse outcomes in hypertrophic cardiomyopathy (HCM) and evaluate the incremental value of predictive power of LVEF in the conventional HCM sudden cardiac death (SCD)-risk model. METHODS: This retrospective study included 1858 patients with HCM from two tertiary hospitals between 2008 and 2019. We classified LVEF into three categories: preserved (≥60%), low normal (50%-60%) and reduced (<50%); there were 1399, 415, and 44 patients with preserved, low-normal, and reduced LVEF, respectively. The primary outcome was a composite of SCD, ventricular tachycardia/fibrillation and appropriate implantable cardioverter-defibrillator shocks. Secondary outcomes were hospitalisation for heart failure (HHF), cardiovascular death and all-cause death. RESULTS: During the median follow-up of 4.09 years, the primary outcomes occurred in 1.9%. HHF, cardiovascular death, and all-cause death occurred in 3.3%, 1.9%, and 5.3%, respectively. Reduced LVEF was an independent predictor of SCD/equivalent events (adjusted HR (aHR) 5.214, 95% CI 1.574 to 17.274, p=0.007), adding predictive value to the HCM risk-SCD model (net reclassification improvement 0.625). Compared with patients with HCM with preserved LVEF, those with low-normal and reduced LVEF had a higher risk of HHF (LVEF 50%-60%, aHR 2.457, 95% CI 1.423 to 4.241, p=0.001; LVEF <50%, aHR 7.937, 95% CI 3.315 to 19.002, p<0.001) and cardiovascular death (LVEF 50%-60%, aHR 2.641, 95% CI 1.314 to 5.309, p=0.006; LVEF <50%, aHR 5.405, 95% CI 1.530 to 19.092, p=0.009), whereas there was no significant association with all-cause death. CONCLUSIONS: Low-normal LVEF was an independent predictor of HHF and cardiovascular death in patients with HCM.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Choi YJ, Kim HK, Hwang IC, et al. Prognosis of patients with hypertrophic cardiomyopathy and low-normal left ventricular ejection fraction. Heart. 2023. PMID: 36581445. doi:10.1136/heartjnl-2022-321853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。